Cellectar announces publication of data from its expansion cohort of the phase ii clover-1 study iopofosine i-131 in relapsed/refractory multiple myeloma in nature's blood cancer journal

Initial data show orr of 50% in quad-class refractory multiple myeloma patients who have failed anti-bcma immunotherapy with median of nine lines of prior therapy initial data show orr of 50% in quad-class refractory multiple myeloma patients who have failed anti-bcma immunotherapy with median of nine lines of prior therapy
CLRB Ratings Summary
CLRB Quant Ranking